Immunocompromised Children with Severe Adenoviral Respiratory Infection
Table 3
Patient and clinical characteristics stratified by survival.
Characteristic
Nonsurvivors
Survivors
value
()
()
Age (years)
3.9 (3.0–12.7)
3.9 (1.8–11.2)
0.56
Female gender, (%)
8 (72%)
3 (38%)
0.18
Cause of immunocompromised state, (%)
0.015
Solid organ transplant
1 (13%)
2 (25%)
Blood and marrow transplant
8 (73%)
1 (13%)
Human immunodeficiency virus
0
0
Neutropenia
2 (28%)
1 (13%)
Congenital immunodeficiency
0
4 (50%)
Hospital LOS (days)
46 (17–145)
45 (19–88)
0.90
ICU LOS (days)
19 (7–48)
24 (7–46)
0.80
Mechanical ventilation
11 (100%)
6 (75%)
0.16
Ventilator days
14 (5–34)
5 (0–21)
0.17
Acute respiratory distress syndrome
6 (55%)
1 (13%)
0.15
Multiple organ dysfunction syndrome
10 (91%)
1 (13%)
0.001
Renal replacement therapy
7 (64%)
0
0.01
Extracorporeal life support
1 (13%)
0
0.58
PIM3 predicted mortality (percent)
5.6 (5.3–6.5)
1.1 (1.1–3.3)
0.011
Antiviral treatment
9 (82%)
4 (50%)
0.32
Treatment with cidofovir
9 (82%)
1 (13%)
0.005
Coinfection
4 (36%)
4 (50%)
0.66
Viral coinfection
4 (36%)
3 (38%)
0.38
Bacterial coinfection
2 (18%)
1 (13%)
1
Absolute lymphocyte count (cells/mm3)
480 (40–650)
1150 (459–4070)
0.13
Values expressed as (%). Continuous variables are shown as median (interquartile range). ICU: intensive care unit; LOS: length of stay; PIM3: Paediatric Index of Mortality 3.
